4-carbamoylimidazolium 5-olate profile

4-carbamoylimidazolium 5-olate: purine antagonist; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-hydroxyimidazole-4-carboxamide : A hydroxyimidazole that is 5-hydroxyimidazole in which the hydrogen at position 4 is replaced by an aminocarbonyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	124343
CHEMBL ID	4303691
CHEBI ID	88290
SCHEMBL ID	3025277
SCHEMBL ID	13219030
MeSH ID	M0104540

Synonym
AC-7529
5-hydroxy-1h-imidazole-4-carboxamide
1h-imidazole-4-carboxamide, 5-hydroxy-
nsc-266026
56973-26-3
nsc266026
sm-108
5-hydroxyimidazole 4-carboxamide
4-carbamoylimidazolium 5-olate
3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-alpha-ol, decahydro-3,6,9-trimethyl-, propionate (ester)
sm 108
alpha-propionyl-dihydroartemether
5-hydroxy-3h-imidazole-4-carboxylic acid amide
4-hydroxy-1h-imidazole-5-carboxamide
AKOS006287688
AKOS015917867
unii-u6iz97918f
nsc 266026
u6iz97918f ,
FT-0630153
4-carbamoyl-5-hydroxyimidazole
bredinin aglycone
SCHEMBL3025277
4-carbamoyl-imidazolium-5-olate
4-carbamoylimidazolium-5-olate
4-carbamoylimidazolium-5 olate
UEWSIIBPZOBMBL-UHFFFAOYSA-N
mfcd06797616
SCHEMBL13219030
mizoribine aglycone
CHEBI:88290
5-hydroxyimidazole-4-carboxamide
4(5)-hydroxy-5(4)-imidazolecarboxamide
mizoribine base
5-hydroxy-3h-imidazole-4-carboxamide
DTXSID60205574
J-517594
Q27160166
CS-0024727
HY-106048
DS-10728
AMY15291
5-hydroxy-1h-imidazole-4-carboxamide inverted exclamation mark inverted exclamation mark
ff-10501-01
CHEMBL4303691
5-hydroxy-1h-imidazole-4-carboxamide;sm-108
56973-26-3 (free base)
un5-hydroxy-1h-imidazole-4-carboxamide
ff-10501
EN300-221830
Z1198170628

Excerpt	Relevance	Reference
"Phase I study with a new oral purine antagonist, SM-108, was conducted in a total of 73 cases in a 5-day consecutive schedule with the dosage ranging from 20-2,500 mg/m2 at II institutes."	( [Phase I study and early phase II of SM-108 (4-carbamoylimidazolium-5-olate) in lung cancer. SM-108 Study Group]. Kimura, K; Miyazaki, T; Ogawa, M; Ohno, R; Ota, K; Sakai, Y; Suzuoki, Y; Uzuka, Y; Yamada, K; Yoshida, T, 1989)	0.28
" The duration of drug action was short, and the daily dosage required adjustment at frequent intervals."	( [Clinical trial of SM-108 in myeloproliferative disorders]. Katayama, N; Kobayashi, T; Minami, N; Morita, K; Mukai, K; Nishikawa, M; Sekine, T; Takeda, M; Tamaki, S; Tanaka, H, 1987)	0.27

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
hydroxyimidazole	Any member of the class of imidazoles in which the imidazole ring is substituted by one or more hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	11 (91.67)	18.7374
1990's	1 (8.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (25.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (75.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	6.96	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
xanthine 7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.	1.97	1	xanthine	Saccharomyces cerevisiae metabolite
5-carbamoyl-1h-imidazol-4-yl-piperonylate 5-carbamoyl-1H-imidazol-4-yl-piperonylate: structure given in first source	2.65	3
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	6.96	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
guanosine monophosphate Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase.	1.96	1	guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	biomarker; Escherichia coli metabolite; metabolite; mouse metabolite
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.37	2	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
methylnitronitrosoguanidine Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position	1.96	1	nitroso compound	alkylating agent

Condition	Relationship Strength	Studies	Trials
Experimental Leukemia [description not available]	2.36	2	0
Leukemia L5178 An experimental lymphocytic leukemia of mice.	1.96	1	0
Leukemia L 1210 [description not available]	2.36	2	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.88	4	0
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.65	3	0
Cancer of Colon [description not available]	2.37	2	0
Experimental Neoplasms [description not available]	2.65	3	0
Sarcoma 180 An experimental sarcoma of mice.	2.37	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.37	2	0
Experimental Mammary Neoplasms [description not available]	1.96	1	0
Granulocytic Leukemia, Chronic [description not available]	3.76	2	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	3.76	2	1
Adenocarcinoma, Basal Cell [description not available]	3.36	1	1
Cancer of Lung [description not available]	4.04	3	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.36	1	1
Lung Neoplasms Tumors or cancer of the LUNG.	4.04	3	1
Leukemia, Smoldering [description not available]	3.36	1	1
Cholera Infantum [description not available]	3.36	1	1
Leucocythaemia [description not available]	3.76	2	1
Germinoblastoma [description not available]	3.36	1	1
Dysmyelopoietic Syndromes [description not available]	3.76	2	1
Erythremia [description not available]	3.36	1	1
Myelomonocytic Leukemia, Chronic [description not available]	3.36	1	1
Anemia, Refractory, with Excess of Blasts Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.	3.36	1	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	3.76	2	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	3.36	1	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	3.76	2	1
Polycythemia Vera A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.	3.36	1	1
Leukemia, Myelomonocytic, Chronic A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.	3.36	1	1
Granulocytic Leukemia [description not available]	3.35	1	1
Hemorrhagic Thrombocythemia [description not available]	3.35	1	1
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	3.35	1	1
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	3.35	1	1
Thrombocythemia, Essential A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.	3.35	1	1
Breast Cancer [description not available]	1.96	1	0
Cancer of Cervix [description not available]	1.96	1	0
Benign Neoplasms [description not available]	1.96	1	0
Cancer of Ovary [description not available]	1.96	1	0
Cancer of Stomach [description not available]	1.96	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1.96	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	1.96	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1.96	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1.96	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	1.96	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.96	1	0

4-carbamoylimidazolium 5-olate

Description

Cross-References

Synonyms (51)

Research Excerpts

Dosage Studied

Roles (1)

Drug Classes (2)

Research

Studies (12)

Market Indicators

Research Demand Index: 11.50

Study Types